A repair story with a changed lead
TB-500 and thymosin beta-4: a change of cast
The repair story often gives TB-500 the lead. Most of the cited experiments gave the part to a different molecule.
The molecule changes before the story ends
I distrust a repair headline that quietly changes its subject halfway through. TB-500 is the synthetic Ac-LKKTETQ fragment of thymosin beta-4; much of the encouraging wound and cardiac research used the full-length protein. That substitution is the reason this site exists.
The distinction is unusually concrete. The equine doping-control paper identifies TB-500 as an acetylated LKKTETQ peptide, corresponding to residues 17–23 of thymosin beta-4. The parent protein has 43 amino acids, the small units of a protein chain. TB-500 has 7. A shared stretch of sequence gives the fragment a biological rationale, but it does not give it every result earned by the whole chain.
The parent protein is released by platelets and macrophages at injury sites and has been studied for cell movement, scarring and blood-vessel growth. TB-500 itself is a synthetic construct. Calling both substances “thymosin” does not make them interchangeable.
Ac-LKKTETQ is the sequence, not a healing claim
The TB-500 sequence is LKKTETQ with an acetyl group at the front, written Ac-LKKTETQ. “TB” refers to thymosin beta-4. It is a peptide, not a steroid, and the number in its name is not a dose.
Actin helps build the internal framework that lets a cell hold its shape and move. A structural study of a thymosin beta-4 hybrid bound to actin showed how the full protein holds actin in reserve. The fragment’s actin-binding region gives a reason to investigate it; tissue repair in a person remains unproved.
The effortless jump bothers me from a shared binding region to a shared clinical outcome. Even full-length thymosin beta-4 produced an awkward result in mice with more regenerating muscle fibers but no significant gain in strength. The muscle research deserves its own telling.
The fragment turns up at the racetrack
One of the clearest papers about TB-500 itself reports detection, with healing outside its scope. In 2012, Ho and colleagues detected TB-500 and its breakdown products in horse plasma and urine using liquid chromatography–mass spectrometry, a method that separates molecules and identifies them by mass.
That is a wonderfully inconvenient origin for a recovery story: the analytical record can establish which fragment is present without establishing that it repairs an injury. I regard that difference as more revealing than another list of possible benefits.
The tissue-repair experiments tell a different story about the parent protein, including attempts to deliver it directly to damaged tissue. Community accounts describe feelings and recovery experiences. Those accounts are anecdotal, not clinical evidence.
FDA names the fragment explicitly
FDA identifies “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500” and warns about missing important safety information. The agency also cites potential immunogenicity with certain routes—the possibility of an immune reaction. The absence of completed controlled human fragment trials cannot be filled by a parent-protein study.
On FDA’s page current as of April 22, 2026, TB-500 appears in the nominated-but-withdrawn table, no longer in Category 2. That is not FDA approval. TB-500 has no approved human therapeutic indication. The FDA and sport record follows the dates without turning an administrative change into permission.
Start with the thymosin beta-4 and TB-500 reading list. The missing human result for the fragment is still missing.